Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women

Lancet

Volumn 359, Issue 9321, 2002, Pages 1919-1920

  Clark, Peter ^d   Twaddle, Sara ^b   Walker, Isobel D ^a   Scott, Linda ^c   Greer, Ian A ^b  

^a Department of Gastroenterology   (United Kingdom)

^b Acad Dept of Obstet and Gynaecol   (United Kingdom)

^c STOBHILL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SCREENING; HEALTH CARE COST; HUMAN; PREGNANCY COMPLICATION; PRIORITY JOURNAL; VEIN THROMBOSIS;

EID: 0036606079     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08740-8     Document Type: Article

References (4)

1. Interaction of the protein C/protein S anticoagulant system, the endothelium and pregnancy
2. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
3. Thrombosis in pregnancy: Maternal and fetal issues
4. The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: Significance of pregnancy-associated activated protein C resistance